Elsevier

The Lancet

Volume 328, Issue 8499, 19 July 1986, Pages 129-131
The Lancet

NEW PURIFIED VERO-CELL VACCINE PREVENTS RABIES IN PATIENTS BITTEN BY RABID ANIMALS

https://doi.org/10.1016/S0140-6736(86)91946-XGet rights and content

Abstract

The protective effect of a new, potentially economical tissue-culture rabies vaccine, purified vero-cell rabies vaccine (PVRV), was tested in 106 patients bitten by animals with proven rabies. 0·5 ml PVRV was given intramuscularly on days 0, 3, 7, 14, 28, and 91; 47 patients with severe exposure were also given 20 IU/kg human rabies immune globulin (HRIG). All patients are alive and well after 1 year. Side-effects of treatment were negligible. Rabies neutralising antibody (≥ 1·6 IU) was demonstrated on day 14 and persisted for 1 year in every case. There was no significant suppression of the antibody response by HRIG. If the untreated mortality is 15%, PVRV is 81% efficient in protecting patients against rabies encephalitis (95% confidence limit). PVRV is likely to replace human diploid-cell strain vaccine as the most widely used tissue-culture rabies vaccine.

References (20)

There are more references available in the full text version of this article.

Cited by (37)

  • Rabies Vaccines

    2017, Plotkin's Vaccines
  • Rabies vaccines

    2012, Vaccines: Sixth Edition
  • The role of vaccination in rabies prevention

    2012, Current Opinion in Virology
    Citation Excerpt :

    In the 1980s another second generation rabies vaccine was developed but this time on a continuous cell line. Vero cells were already being employed in the mass production of inactivated polio vaccines and in 1985 a Vero cell rabies vaccine produced using the PM strain was licensed in France [23]. Continuous cell lines offer the advantage of being able to scale up easily and do not lose their ability to divide after several passages as is the case with primary cell lines.

  • RABIES VIRUS

    2009, Feigin and Cherry's Textbook of Pediatric Infectious Diseases, Sixth Edition
  • Rabies vaccines

    2008, Vaccines
View all citing articles on Scopus
View full text